Josh Ruben Joins PetVivo Holdings, Inc. Board of Directors
PetVivo Holdings (OTCQX: PETV; OTCID PETVW) announced that Josh Ruben has joined its Board of Directors effective Oct. 28, 2025. Ruben is Managing Director of Life Sciences at Trinity Capital and previously spent 12 years in investment banking, most recently as Head of Life Science Tools and Diagnostics coverage at RBC Capital Markets.
The company highlighted Ruben’s experience in healthcare finance, venture lending, and executing multi‑billion‑dollar M&A and capital transactions as qualifications to support PetVivo’s veterinary Spryng® product and potential expansion into human therapeutics.
PetVivo Holdings (OTCQX: PETV; OTCID PETVW) ha annunciato che Josh Ruben è entrato a far parte del consiglio di amministrazione con effetto dal 28 ottobre 2025. Ruben è Managing Director delle Life Sciences presso Trinity Capital e in precedenza ha trascorso 12 anni in banca d'investimento, più recentemente come Responsabile della copertura di Life Science Tools and Diagnostics presso RBC Capital Markets.
L'azienda ha sottolineato l'esperienza di Ruben in finanza sanitaria, prestito venture e nell'esecuzione di operazioni di M&A multimiliardarie e di altre transazioni di capitale come qualifiche per supportare il prodotto veterinario Spryng® di PetVivo e una potenziale espansione nel campo delle terapie umane.
PetVivo Holdings (OTCQX: PETV; OTCID PETVW) anunció que Josh Ruben se unió a su Junta Directiva con efecto a partir del 28 de octubre de 2025. Ruben es Managing Director de Life Sciences en Trinity Capital y anteriormente pasó 12 años en banca de inversión, más recientemente como Responsable de la cobertura de Life Science Tools and Diagnostics en RBC Capital Markets.
La compañía destacó la experiencia de Ruben en finanzas sanitarias, préstamos de venture y en la ejecución de operaciones de fusiones y adquisiciones multimillonarias y de transacciones de capital, como calificaciones para apoyar el producto veterinario Spryng® de PetVivo y una posible expansión en terapias humanas.
PetVivo Holdings (OTCQX: PETV; OTCID PETVW)는 2025년 10월 28일부터 이사회에 합류한 Josh Ruben를 발표했다. Ruben은 Trinity Capital의 Life Sciences 매니징 디렉터이며 이전에는 투자은행 업무를 12년 동안 수행했고, 최근 RBC Capital Markets에서 Life Science Tools and Diagnostics 커버리지 책임자였다.
회사는 Ruben의 헬스케어 금융, 벤처 대출, 다억 달러 규모의 인수합병(M&A) 및 자본 거래 실행 경험이 PetVivo의 수의학용 Spryng® 제품과 인간 치료제로의 확장 가능성을 뒷받침하는 자격으로 강조되었다고 밝혔다.
PetVivo Holdings (OTCQX: PETV; OTCID PETVW) a annoncé que Josh Ruben a rejoint son conseil d'administration à compter du 28 octobre 2025. Ruben est Managing Director des Life Sciences chez Trinity Capital et a précédemment passé 12 ans dans la banque d'investissement, plus récemment comme Responsable de la couverture Life Science Tools and Diagnostics chez RBC Capital Markets.
L'entreprise a mis en avant l'expérience de Ruben en financement de la santé, prêt en capital-risque et exécution d'opérations d'M&A et de transactions de capital multimilliardaires comme qualifications pour soutenir le produit vétérinaire Spryng® de PetVivo et une éventuelle expansion dans les thérapeutiques humaines.
PetVivo Holdings (OTCQX: PETV; OTCID PETVW) gab bekannt, dass Josh Ruben mit Wirkung zum 28. Oktober 2025 dem Vorstand beigetreten ist. Ruben ist Managing Director der Life Sciences bei Trinity Capital und verbrachte zuvor 12 Jahre im Investment Banking, zuletzt als Leiter der Coverage von Life Science Tools and Diagnostics bei RBC Capital Markets.
Das Unternehmen hob Rubens Erfahrung in der Gesundheitsfinanzierung, Venture-Krediten und der Durchführung von M&A- und Kapitaltransaktionen in Milliardenhöhe hervor, als Qualifikationen zur Unterstützung des veterinärmedizinischen Spryng®-Produkts von PetVivo und einer potenziellen Expansion in die Humantherapie.
PetVivo Holdings (OTCQX: PETV; OTCID PETVW) أعلنت أن جوش روبن قد انضم إلى مجلس الإدارة اعتباراً من 28 أكتوبر 2025. روبن هو المدير الإداري لعلوم الحياة في Trinity Capital وقبل ذلك قضى 12 عاماً في المصرفية الاستثمارية، وفي القترة الأخيرة كمدير تغطية أدوات علوم الحياة وال Diagnostics في RBC Capital Markets.
أبرزت الشركة خبرة روبن في التمويل الصحي、 والقروض الرأس مالية، وتنفيذ صفقات اندماج واستحواذ بمليارات الدولارات وصفقات رأس المال كأهلية لدعم منتج PetVivo البيطري Spryng® والاحتمال التوسع في العلاجات البشرية.
PetVivo Holdings (OTCQX: PETV; OTCID PETVW) 宣布，自 2025 年 10 月 28 日起，Josh Ruben 已加入董事会。Ruben 是 Trinity Capital 的生命科学管理董事，此前在投行工作了 12 年，最近在 RBC Capital Markets 担任生命科学工具与诊断覆盖领域主管。
公司强调了 Ruben 在医疗健康金融、风险投资贷款以及执行数十亿美元规模的并购和资本交易方面的经验，作为支持 PetVivo 的兽用 Spryng® 产品及潜在向人类治疗领域扩张的资质。
- Board addition of Josh Ruben on Oct 28, 2025
- Experience: Managing Director, Life Sciences at Trinity Capital
- Investment banking background with 12 years at RBC Capital Markets
- Transaction track record: executed multi‑billion‑dollar M&A and securities deals
- Sector expertise in life sciences and healthcare finance
- None.
MINNEAPOLIS, MN, US, Oct. 28, 2025 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc. (OTCQX: PETV; OTCID PETVW), in cooperation with its wholly-owned subsidiary PetVivo Animal Health, Inc., both emerging biomedical device companies focused on the commercialization of innovative medical therapeutics for companion animals and animal athletes is pleased to announce that Josh Ruben has joined the Company’s Board of Directors.
“We are honored to welcome Josh Ruben to our Board of Directors,” said John Lai, Chief Executive Officer of PetVivo Holdings, Inc. “Josh brings a wealth of experience in healthcare finance, capital markets, and corporate strategy, with a proven track record of executing multi-billion-dollar M&A and capital transactions. His deep understanding of the life sciences industry and his strategic insights into growth-stage companies will be invaluable as we continue to expand PetVivo’s market presence and advance our mission to deliver innovative solutions for the treatment of osteoarthritis and other joint conditions in companion animals.”
Mr. Ruben is the Managing Director of Life Sciences at Trinity Capital where he focuses on venture lending to healthcare companies. Mr. Ruben joined Trinity after 12 years of investment banking, most recently at RBC Capital Markets where he was Head of Life Science Tools and Diagnostics coverage. He is a published expert in corporate finance with a background in economics. He holds degrees from Pomona College and Harvard Business School. Mr. Ruben’s long track record of successful experiences in analyzing life sciences companies, capital investments and his overall finance background including executing billions of dollars of M&A and securities transactions are material factors regarding his qualifications to serve on our Board of Directors.
“I am thrilled to join the Board of Directors of PetVivo Holdings, Inc.,” said Mr. Ruben. “PetVivo’s innovative technology platform, exemplified by its Spryng® veterinary product, stands at the intersection of animal and human health. The Company’s continued growth in the animal health sector, along with its expansion into human therapeutic markets, represents an exciting evolution of its core science and commercialization strategy. I look forward to contributing my experience in healthcare finance and life sciences to help guide PetVivo’s growth, strengthen its capital strategy, and maximize value creation across both veterinary and emerging human applications.”
About PetVivo Holdings, Inc.
PetVivo Holdings Inc. (OTCQX: PETV; OTCID: PETVW), in cooperation with its wholly-owned subsidiary PetVivo Animal Health, Inc., is an emerging biomedical device company currently focused on the manufacturing, commercialization and licensing of innovative medical devices and therapeutics for companion animals. The Company's strategy is to leverage human therapies for the treatment of companion animals in a capital and time efficient way. A key component of this strategy is the accelerated timeline to revenues for veterinary medical devices, which enter the market much earlier than more stringently regulated pharmaceuticals and biologics.
PetVivo has a robust pipeline of products for the treatment of animals and people. A portfolio of twelve patents and six trade secrets protect the Company's biomaterials, products, production processes and methods of use. The Company’s lead products SPRYNG® with OsteoCushion® technology, a veterinarian-administered, intra-articular injection for the management of lameness and other joint related afflictions, including osteoarthritis, in cats, dogs and horses, and PrecisePRP®, a first-in-class, off-the-shelf, platelet-rich
CONTACT:
John Lai, CEO
PetVivo Holdings, Inc.
Email: info1@petvivo.com
(952) 405-6216
Forward-Looking Statements:
The foregoing material may contain “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, each as amended. Forward-looking statements include all statements that do not relate solely to historical or current facts, including without limitation the Company’s proposed development and commercial timelines, and can be identified by the use of words such as “may,” “will,” “expect,” “project,” “estimate,” “anticipate,” “plan,” “believe,” “potential,” “should,” “continue” or the negative versions of those words or other comparable words. Forward-looking statements are not guarantees of future actions or performance. These forward-looking statements are based on information currently available to the Company and its current plans or expectations and are subject to a number of uncertainties and risks that could significantly affect current plans. Risks concerning the Company’s business are described in detail in the Company’s Annual Report on Form 10-K for the year ended March 31, 2025, and other periodic and current reports filed with the Securities and Exchange Commission. The Company is under no obligation to, and expressly disclaims any such obligation to, update or alter its forward-looking statements, whether as a result of new information, future events or otherwise.
FAQ
Who is Josh Ruben and what role did he accept at PetVivo (PETV) on Oct 28, 2025?
What experience does Josh Ruben bring to PetVivo (PETV)?
How might Josh Ruben’s background affect PetVivo’s capital strategy and growth (PETV)?
Does the announcement mention specific financial guidance or transactions for PetVivo (PETV)?
Will Josh Ruben’s appointment influence PetVivo’s Spryng® veterinary product commercialization (PETV)?
Where can investors find the official PetVivo (PETV) disclosure about the board appointment date?
